32-Person Sales Team Targets $2 Billion Long-Term Care Market as Company Marks Major Milestone in Alzheimer’s Treatment
Alpha Cognition (ACOG) has officially launched ZUNVEYL, the first oral FDA-approved treatment for mild to moderate Alzheimer’s disease in over 10 years. The Vancouver- and Dallas-based biopharmaceutical company announced today that all launch activities were completed on time and on budget, positioning ZUNVEYL for early commercial success.
With an estimated $2 billion opportunity in the long-term care (LTC) market, Alpha Cognition has deployed a 32-person sales team — each with an average of 16 years of industry experience and 10 years in LTC — to drive ZUNVEYL’s adoption among healthcare providers. The drug is now available by prescription in three dosages (5 mg, 10 mg, and 15 mg) at pharmacies nationwide.
“The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease,” said Lauren D’Angelo, COO and CCO of Alpha Cognition. “Our team has worked relentlessly to bring this treatment to market — from building out an industry-leading infrastructure to hiring a top-notch sales team — all in record time.”
ZUNVEYL offers a differentiated treatment option for Alzheimer’s patients who have had limited alternatives. The company is also engaging with payers and caregivers to ensure broad access and education for the millions impacted by this progressive neurodegenerative condition.
Alpha Cognition’s entry into the Alzheimer’s market marks a major step in its mission to provide innovative, accessible solutions for neurodegenerative diseases. With launch activities now complete, the company is focused on ensuring that patients receive ZUNVEYL from day one — bringing new hope to patients and caregivers alike.
Read original press release here
You might like this article:Alphabet Eyes $30 Billion Wiz Acquisition to Bolster Cybersecurity and Cloud Business
